Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
5(36%)
Results Posted
50%(2 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_1
1
7%
Ph phase_2
6
43%
Ph not_applicable
3
21%
Ph phase_4
1
7%

Phase Distribution

1

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
6(54.5%)
Phase 4Post-market surveillance
1(9.1%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

14

all time

Status Distribution
Active(6)
Completed(4)
Terminated(1)
Other(3)

Detailed Status

Completed4
Recruiting4
unknown3
Active, not recruiting1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
5
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (9.1%)
Phase 26 (54.5%)
Phase 41 (9.1%)
N/A3 (27.3%)

Trials by Status

completed429%
active_not_recruiting17%
not_yet_recruiting17%
terminated17%
unknown321%
recruiting429%

Recent Activity

5 active trials
Showing 5 of 14
not_yet_recruitingphase_2

Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC

NCT07663747
recruitingphase_2

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

NCT05312671
recruitingnot_applicable

Ablative Technique For Ovarian Preservation In Endometrioma

NCT07119060
recruitingphase_4

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

NCT06764095
completedphase_2

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)

NCT03674424
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT07663747Phase 2

Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC

Not Yet Recruiting
NCT05312671Phase 2

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Recruiting
NCT07119060Not Applicable

Ablative Technique For Ovarian Preservation In Endometrioma

Recruiting
NCT06764095Phase 4

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Recruiting
NCT03674424Phase 2

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)

Completed
NCT04289779Phase 2

Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

Active Not Recruiting
NCT05153694

Infectious Complications After Cystectomy: A Prospective Observational Study

Recruiting
NCT06115434

Comparing Operative, Postoperative and Quality of Life of Patients After Salvage and Radical Cystectomy

Unknown
NCT03912818Phase 2

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Terminated
NCT02924480Not Applicable

Intravenous Lidocaine for Cystectomy Procedures

Completed
NCT04626336

Post-operative Hernias After Radical Cystectomy

Unknown
NCT01938573Phase 1

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

Completed
NCT02984774Not Applicable

Assessment of Telomerase Activity in Endometrial Tissue and Serum in Endometriosis Patients

Completed
NCT01596985Phase 2

Ovarian Endometrioma Ablation Using Plasma Energy Versus Cystectomy

Unknown

All 14 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
14